Novel infusion strategy to reduce major side effects caused by anti-GD2 monoclonal antibody naxitamab without affecting its pharmacokinetics Meeting Abstract
| Authors: | Mora, J.; Varo, A.; Castañeda, A.; Chamorro, S.; Muñoz, J. P.; Gorostegui, M.; Celma, M. S.; Lopez, S.; Simao, M.; Perez-Jaume, S.; Cheung, I. Y.; Cheung, N. K. V. |
| Abstract Title: | Novel infusion strategy to reduce major side effects caused by anti-GD2 monoclonal antibody naxitamab without affecting its pharmacokinetics |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302790 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.e14502 |
| Notes: | Meeting Abstract: e14502 -- Meeting also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
